to remember that, it is the host immune system that is ultimately responsible for
success in combating bacterial disease.
References
Aarestrup F, Bager F, Jensen NE, Madsen M, Meyling A, Wegener HC (1998) Surveillance of
antimicrobial resistance in bacteria isolates from food animals to antimicrobial growth pro-
moters and related therapeutic agents in Denmark. Acta Pathol Microbiol Immunol Scand
106:606–622
Asad S, Opal S (2008) Bench-to-bedside review: quorum sensing and the role of cell-to-cell
communication during invasive bacterial infection. Crit Care (London) 12:236–247
Bager F, Emborg H-D, Aarestrup FM, Wegener, HC (2002) DANMAP 2001: The Danish
Experience Following the Ban of Antimicrobial Growth Promoters: Trends in Microbial
Resistance and Antimicrobial Use. Proceedings of Alltech’s 18th Annual Symposium: from
niche markets to mainstream, Lexington, Kentucky, USA, 13–15 May
Ball KR, Rubin JE, Chirino-Trejo M, Dowling PM (2008) Antimicrobial resistance and prevalence
of canine uropathogens at the Western College of Veterinary Medicine Veterinary Teaching
Hospital, 2002–2007. Can Vet J 49:985–990
Baquero F (1990) Resistance to quinolones in gram-negative microorganisms: mechanisms and
prevention. Eur Urol 17(Suppl 1):3–12
Baquero F, Negri MC (1997) Strategies to minimize the development of antibiotic resistance.
J Chemother 9(Suppl 3):29–37
Bedenic B, Vranes J, Suto S, Zagar Z (2005) Bactericidal activity of oral beta-lactam antibiotics in
plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-
spectrum beta-lactamases. Int J Antimicrob Agents 25:479–487
Benitez de Cruz L (2008) Extreme bacteria, Scienceray at:http://www.scienceray.com/Biology/
Microbiology/Extreme-Bacteria.211065
Blondeau JM, Hansen G, Metzler K, Hedlin P (2004) The role of PK/PD parameters to avoid
selection and increase of resistance: Mutant prevention concentrations. J Chemother 16
(Suppl 3):1–19
Boak LM, Li J, Rayner CR, Nation RL (2007) Pharmacokinetic/pharmacodynamic factors
influencing emergence of resistance to linezolid in an in vitro model. Antimicrob Agents
Chemother 51:1287–1292
Boy D, Well M, Kinzig-Schippers M, So ̋rgel F, Ankel-Fuchs D, Naber KG (2004) Urinary
bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg)
versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. Int J Antimicrob
Agents 23(Suppl 1):S6–S16
Boyen F, Eeckhaut V, Van Immerseel F, Pasmans F, Ducatelle R, Haesebrouck F (2009) Quorum
sensing in veterinary pathogens: mechanisms, clinical importance and future perspectives. Vet
Microbiol 135:187–195
Bronzwaer S (2008) Harmonised monitoring of antimicrobial resistance in Salmonella and
Campylobacter isolates from food animals in the European Union. Clin Microbiol Infect
14:522–533
Bywater R, Simjee S, Silley P (2006) Antimicrobial breakpoints - definitions and conflicting
requirements. Vet Microbiol 118:158–159
Casewell M, Friis C, Marco E, McMullinP PI (2003) The European ban on growth-promoting
antibiotics and emerging consequences for human and animal health. J Antimicrob Chemother
52:159–161
Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ (2008) The biology and future prospects of
antivirulence therapies. Nat Rev Microbiol 6:17–27
258 M. Martinez and P. Silley